Sanara MedTech Inc. (SMTI)
USD 31.79
(-6.47%)
USD 31.79
(-6.47%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 61.12 Million USD | 18.2% |
| 2022 | 51.71 Million USD | 77.05% |
| 2021 | 29.2 Million USD | 53.93% |
| 2020 | 18.97 Million USD | 43.89% |
| 2019 | 13.18 Million USD | 126.6% |
| 2018 | 5.81 Million USD | 8.66% |
| 2017 | 5.35 Million USD | 10.74% |
| 2016 | 4.83 Million USD | 40.38% |
| 2015 | 3.44 Million USD | -11.47% |
| 2014 | 3.89 Million USD | 0.76% |
| 2013 | 3.86 Million USD | -33.03% |
| 2012 | 5.76 Million USD | 79.27% |
| 2011 | 3.21 Million USD | -6.56% |
| 2010 | 3.44 Million USD | 235.87% |
| 2009 | 1.02 Million USD | -37.2% |
| 2008 | 1.63 Million USD | 100.7% |
| 2007 | 813.05 Thousand USD | 67.79% |
| 2006 | 484.58 Thousand USD | -39.5% |
| 2005 | 800.99 Thousand USD | -86.94% |
| 2004 | 6.13 Million USD | 0.0% |
| 2001 | 1.44 Million USD | -19.75% |
| 2000 | 1.8 Million USD | 8.37% |
| 1999 | 1.66 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 17.13 Million USD | 0.89% |
| 2024 Q2 | 19.94 Million USD | 16.36% |
| 2023 Q3 | 15.86 Million USD | 0.44% |
| 2023 Q4 | 16.98 Million USD | 7.1% |
| 2023 FY | 61.12 Million USD | 18.2% |
| 2023 Q2 | 15.79 Million USD | 4.83% |
| 2023 Q1 | 15.06 Million USD | -5.6% |
| 2022 Q1 | 9.78 Million USD | 1.24% |
| 2022 Q2 | 11.9 Million USD | 21.71% |
| 2022 Q4 | 15.95 Million USD | 14.49% |
| 2022 Q3 | 13.93 Million USD | 17.06% |
| 2022 FY | 51.71 Million USD | 77.05% |
| 2021 Q2 | 6.76 Million USD | 20.44% |
| 2021 FY | 29.2 Million USD | 53.93% |
| 2021 Q3 | 7.16 Million USD | 5.81% |
| 2021 Q4 | 9.66 Million USD | 34.95% |
| 2021 Q1 | 5.61 Million USD | 9.07% |
| 2020 Q3 | 5.16 Million USD | 39.67% |
| 2020 Q2 | 3.69 Million USD | -25.44% |
| 2020 Q4 | 5.15 Million USD | -0.27% |
| 2020 FY | 18.97 Million USD | 43.89% |
| 2020 Q1 | 4.96 Million USD | 11.07% |
| 2019 Q2 | 3 Million USD | 27.65% |
| 2019 FY | 13.18 Million USD | 126.6% |
| 2019 Q4 | 4.46 Million USD | 32.85% |
| 2019 Q3 | 3.36 Million USD | 11.83% |
| 2019 Q1 | 2.35 Million USD | 378.14% |
| 2018 Q3 | 1.58 Million USD | -23.55% |
| 2018 Q2 | 2.07 Million USD | 23.62% |
| 2018 Q1 | 1.67 Million USD | 14.29% |
| 2018 FY | 5.81 Million USD | 8.66% |
| 2018 Q4 | 492.47 Thousand USD | -68.88% |
| 2017 Q4 | 1.46 Million USD | 8.71% |
| 2017 Q1 | 1.37 Million USD | 20.73% |
| 2017 Q3 | 1.34 Million USD | 15.21% |
| 2017 Q2 | 1.16 Million USD | -14.81% |
| 2017 FY | 5.35 Million USD | 10.74% |
| 2016 Q3 | 981.73 Thousand USD | -49.69% |
| 2016 Q1 | 765.71 Thousand USD | -7.62% |
| 2016 Q2 | 1.95 Million USD | 154.86% |
| 2016 FY | 4.83 Million USD | 40.38% |
| 2016 Q4 | 1.13 Million USD | 15.86% |
| 2015 Q2 | 882.95 Thousand USD | -1.12% |
| 2015 Q3 | 840.4 Thousand USD | -4.82% |
| 2015 FY | 3.44 Million USD | -11.47% |
| 2015 Q1 | 892.93 Thousand USD | 5.52% |
| 2015 Q4 | 828.9 Thousand USD | -1.37% |
| 2014 Q4 | 846.24 Thousand USD | -22.46% |
| 2014 Q3 | 1.09 Million USD | 6.31% |
| 2014 Q2 | 1.02 Million USD | 10.72% |
| 2014 Q1 | 927.2 Thousand USD | -59.52% |
| 2014 FY | 3.89 Million USD | 0.76% |
| 2013 Q3 | 565.43 Thousand USD | 22.49% |
| 2013 Q2 | 461.6 Thousand USD | -17.97% |
| 2013 Q1 | 562.73 Thousand USD | -82.19% |
| 2013 FY | 3.86 Million USD | -33.03% |
| 2013 Q4 | 2.29 Million USD | 305.11% |
| 2012 FY | 5.76 Million USD | 79.27% |
| 2012 Q4 | 3.15 Million USD | 67.12% |
| 2012 Q3 | 1.89 Million USD | 270.76% |
| 2012 Q2 | 509.89 Thousand USD | 146.51% |
| 2012 Q1 | 206.84 Thousand USD | -68.68% |
| 2011 Q1 | 1.31 Million USD | -10.06% |
| 2011 FY | 3.21 Million USD | -6.56% |
| 2011 Q4 | 660.47 Thousand USD | 28.95% |
| 2011 Q3 | 512.18 Thousand USD | -43.8% |
| 2011 Q2 | 911.35 Thousand USD | -30.8% |
| 2010 FY | 3.44 Million USD | 235.87% |
| 2010 Q1 | 505.78 Thousand USD | 36.48% |
| 2010 Q2 | 705.47 Thousand USD | 39.48% |
| 2010 Q3 | 766.65 Thousand USD | 8.67% |
| 2010 Q4 | 1.46 Million USD | 91.0% |
| 2009 Q2 | 189.02 Thousand USD | -12.3% |
| 2009 Q3 | 241.66 Thousand USD | 27.85% |
| 2009 Q1 | 215.53 Thousand USD | -71.35% |
| 2009 Q4 | 370.59 Thousand USD | 53.35% |
| 2009 FY | 1.02 Million USD | -37.2% |
| 2008 Q4 | 752.4 Thousand USD | 93.93% |
| 2008 Q2 | 219.85 Thousand USD | -19.05% |
| 2008 Q1 | 271.6 Thousand USD | 5.94% |
| 2008 FY | 1.63 Million USD | 100.7% |
| 2008 Q3 | 387.97 Thousand USD | 76.47% |
| 2007 Q2 | 162.17 Thousand USD | -19.76% |
| 2007 FY | 813.05 Thousand USD | 67.79% |
| 2007 Q4 | 256.38 Thousand USD | 33.25% |
| 2007 Q3 | 192.4 Thousand USD | 18.64% |
| 2007 Q1 | 202.1 Thousand USD | 65.49% |
| 2006 Q2 | 122.9 Thousand USD | -0.05% |
| 2006 Q1 | 122.96 Thousand USD | -12.71% |
| 2006 Q3 | 118.09 Thousand USD | -3.92% |
| 2006 Q4 | 122.12 Thousand USD | 3.42% |
| 2006 FY | 484.58 Thousand USD | -39.5% |
| 2005 FY | 800.99 Thousand USD | -86.94% |
| 2005 Q4 | 140.87 Thousand USD | 6.84% |
| 2005 Q2 | 331.76 Thousand USD | 92.33% |
| 2005 Q1 | 172.49 Thousand USD | 720.13% |
| 2005 Q3 | 131.85 Thousand USD | -60.26% |
| 2004 Q4 | 21.03 Thousand USD | -99.64% |
| 2004 FY | 6.13 Million USD | 0.0% |
| 2004 Q3 | 5.89 Million USD | 4346.76% |
| 2004 Q2 | 132.57 Thousand USD | 55.78% |
| 2004 Q1 | 85.09 Thousand USD | 0.0% |
| 2002 Q1 | 303.48 Thousand USD | -15.86% |
| 2001 Q4 | 360.7 Thousand USD | -1.99% |
| 2001 Q1 | 389.08 Thousand USD | -54.82% |
| 2001 FY | 1.44 Million USD | -19.75% |
| 2001 Q3 | 368.02 Thousand USD | 51.58% |
| 2001 Q2 | 242.79 Thousand USD | -37.6% |
| 2000 FY | 1.8 Million USD | 8.37% |
| 2000 Q2 | 326.27 Thousand USD | 8.36% |
| 2000 Q3 | 316.23 Thousand USD | -3.08% |
| 2000 Q1 | 301.1 Thousand USD | 0.0% |
| 2000 Q4 | 861.21 Thousand USD | 172.34% |
| 1999 FY | 1.66 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 104.27 Million USD | 41.376% |
| AngioDynamics, Inc. | 252.41 Million USD | 75.783% |
| AtriCure, Inc. | 327.05 Million USD | 81.31% |
| Avinger, Inc. | 18.63 Million USD | -227.971% |
| Azenta, Inc. | 336.26 Million USD | 81.822% |
| BioLife Solutions, Inc. | 117.57 Million USD | 48.011% |
| The Cooper Companies, Inc. | 1.82 Billion USD | 96.65% |
| Daxor Corporation | 1.28 Million USD | -4673.64% |
| Ekso Bionics Holdings, Inc. | 24.19 Million USD | -152.686% |
| Femasys Inc. | 15.2 Million USD | -302.144% |
| GlucoTrack, Inc. | 7.1 Million USD | -760.461% |
| Harvard Bioscience, Inc. | 58.58 Million USD | -4.346% |
| Hologic, Inc. | 1.34 Billion USD | 95.456% |
| ICU Medical, Inc. | 717.04 Million USD | 91.475% |
| Intuitive Surgical, Inc. | 2.96 Billion USD | 97.937% |
| KORU Medical Systems, Inc. | 26.1 Million USD | -134.133% |
| LeMaitre Vascular, Inc. | 90.33 Million USD | 32.334% |
| Innovative Eyewear, Inc. | -119.32 Thousand USD | 51325.752% |
| Innovative Eyewear, Inc. | -119.32 Thousand USD | 51325.752% |
| Masimo Corporation | 867 Million USD | 92.95% |
| Microbot Medical Inc. | 9.85 Million USD | -520.266% |
| Meihua International Medical Technologies Co., Ltd. | 18.42 Million USD | -231.851% |
| Merit Medical Systems, Inc. | 459.92 Million USD | 86.709% |
| Nephros, Inc. | 9.78 Million USD | -524.767% |
| NovoCure Limited | 613.92 Million USD | 90.043% |
| NEXGEL, Inc. | 4.09 Million USD | -1392.363% |
| NEXGEL, Inc. | 4.09 Million USD | -1392.363% |
| Singular Genomics Systems, Inc. | 102.24 Million USD | 40.214% |
| OraSure Technologies, Inc. | 125.34 Million USD | 51.232% |
| Pro-Dex, Inc. | 7.37 Million USD | -728.506% |
| Pulse Biosciences, Inc. | 43.57 Million USD | -40.284% |
| Predictive Oncology Inc. | 15.22 Million USD | -301.373% |
| Precision Optics Corporation, Inc. | 8.52 Million USD | -617.278% |
| QuidelOrtho Corporation | 1.35 Billion USD | 95.49% |
| Repligen Corporation | 261.12 Million USD | 76.591% |
| STAAR Surgical Company | 224.55 Million USD | 72.778% |
| Sharps Technology, Inc. | 10.12 Million USD | -503.627% |
| Utah Medical Products, Inc. | 13.26 Million USD | -360.955% |
| DENTSPLY SIRONA Inc. | 1.79 Billion USD | 96.593% |
| Jin Medical International Ltd. | 3.91 Million USD | -1460.333% |